LINK TO RESEARCH
International journal of obesity and related metabolic disorders
P A Velasquez-Mieyer 1 ,
G E Umpierrez,
R H Lustig,
A K Cashion,
P A Cowan,
K A Spencer,
G A Burghen
Objective: This study investigated (1) the effect of octreotide-LAR (Sandostatin-LAR
Depot; Novartis) on the enteroinsular axis in a biracial cohort of severely
obese adults, (2) whether octreotide suppression of insulin secretion
occurs by both a direct beta-cell effect and through mediating a
glucagon-like peptide 1 (GLP-1) response, and (3) whether differences in
GLP-1 concentrations could explain racial differences in insulin
Design: Prospective, open-label trial using a pre-post test design.
Setting: Single university, clinical research center.
Subjects: In all, 42 healthy, severely obese Caucasian and African-American (AA)
adults (93% female, 64% Caucasian, age=37.8+/-1.2 y, weight=123+/-4.2 kg,
BMI=44.5+/-1 kg/m(2)), recruited through physician referral and newspaper
ads, participated in the study.
Interventions: Indices of beta-cell activity, insulin and GLP-1 response before and
during a 75-gm oral glucose tolerance test were determined before and after
24 weeks of octreotide-LAR.
Results: AA exhibited higher beta-cell activity, and insulin and GLP-1
concentrations than Caucasians. Octreotide-LAR suppressed the insulin and
GLP-1 levels in both groups.
Interested in this research and working with us? Please contact us here.